CN104257762B - A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of - Google Patents
A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of Download PDFInfo
- Publication number
- CN104257762B CN104257762B CN201410551423.2A CN201410551423A CN104257762B CN 104257762 B CN104257762 B CN 104257762B CN 201410551423 A CN201410551423 A CN 201410551423A CN 104257762 B CN104257762 B CN 104257762B
- Authority
- CN
- China
- Prior art keywords
- cervi
- lupuli
- flos
- glycopeptide
- ligustri lucidi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001009 osteoporotic effect Effects 0.000 title claims abstract description 13
- 230000002265 prevention Effects 0.000 title abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 241000628997 Flos Species 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 102000002068 Glycopeptides Human genes 0.000 claims abstract description 37
- 108010015899 Glycopeptides Proteins 0.000 claims abstract description 37
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims abstract description 36
- 150000001669 calcium Chemical class 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229930003944 flavone Natural products 0.000 claims abstract description 22
- 235000011949 flavones Nutrition 0.000 claims abstract description 22
- 150000002213 flavones Chemical class 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 6
- 238000009472 formulation Methods 0.000 claims abstract 3
- 239000008187 granular material Substances 0.000 claims abstract 2
- 239000007902 hard capsule Substances 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims abstract 2
- 239000007901 soft capsule Substances 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- -1 let cool Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 24
- 229910052791 calcium Inorganic materials 0.000 abstract description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 22
- 210000000988 bone and bone Anatomy 0.000 abstract description 22
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 229930003316 Vitamin D Natural products 0.000 abstract description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 8
- 235000019166 vitamin D Nutrition 0.000 abstract description 8
- 239000011710 vitamin D Substances 0.000 abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 8
- 229940046008 vitamin d Drugs 0.000 abstract description 8
- 239000000047 product Substances 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 3
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 208000001132 Osteoporosis Diseases 0.000 description 19
- 241000700159 Rattus Species 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 9
- 238000009835 boiling Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000037182 bone density Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 3
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 3
- 241000282994 Cervidae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229930008679 prenylflavonoid Natural products 0.000 description 3
- 150000007951 prenylflavonoids Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 2
- 241000283026 Cervus elaphus Species 0.000 description 2
- 241000283007 Cervus nippon Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039984 Senile osteoporosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 238000004380 ashing Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 2
- 235000008209 xanthohumol Nutrition 0.000 description 2
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000001203 anti-plasmodial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004221 bone function Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003138 coordinated effect Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- JFCCOFVNZMTDAN-UHFFFAOYSA-N dehydrocycloxanthohumol hydrate Natural products COC1=CC2OC(C)(C)C(O)CC2C(=C1C(=O)C=Cc3ccc(O)cc3)O JFCCOFVNZMTDAN-UHFFFAOYSA-N 0.000 description 1
- FUSADYLVRMROPL-UXBLZVDNSA-N desmethylxanthohumol Chemical compound CC(C)=CCC1=C(O)C=C(O)C(C(=O)\C=C\C=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UXBLZVDNSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229940074446 sodium potassium tartrate tetrahydrate Drugs 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- GUQGMEWOCKDLDE-RMKNXTFCSA-N xanthohumol B Chemical compound COC1=CC=2OC(C)(C)C(O)CC=2C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 GUQGMEWOCKDLDE-RMKNXTFCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
One has auxiliary prevention and treats osteoporotic natural drug composition, it is characterized in that this compositions is by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Bovis seu Bubali glycopeptide, Os Bovis seu Bubali activated calcium and Fructus Ligustri Lucidi extract composition, with traditional Chinese medical science the kidney invigorating, bone and muscle strengthening, replenishing QI to invigorate the spleen, tune liver of invigorating blood circulation is basic point, in conjunction with supplement calcium, vitamin D and activated product thereof, replenishing collagen, the different mechanism of action such as sex hormone level regulation sets out, utilize the synergism of each composition, reach prevention and treat osteoporotic effect, oral formulations can be made, such as hard capsule, soft capsule, tablet, granule, powder, pill, teabag, medicated wine.Said composition can be applicable to Chinese patent medicine or health food.
Description
Technical field
The present invention helps to prevention about one and treats osteoporotic natural drug composition, belongs to medicine and field of food.
Background technology
Osteoporosis (osteoporosis, OP) is a kind of with Low BMD and osseous tissue Microstructure Fracture for feature, causes sclerotin fragility to increase and is prone to the general bone metabolic disease of fracture.Primary disease is common in old people, but each period at age all can fall ill.Osteoporosis can be divided into constitutional and Secondary cases two class.Primary osteoporosis means other illness not causing primary disease；Secondary osteoporosis is then that the osseous tissue amount caused due to various generals or endocrine metabolism disease reduces.Along with social population's aging day by day, the sickness rate of osteoporosis increases day by day, huge misery is brought to patient, family and society be also result in white elephant, fracture pre-for anti-curing osteoporosis, anti-is put in status of equal importance by medical circle with treatment hyperlipidemia prevention myocardial infarction, treatment hypertension prevention apoplexy, and the preventing and controlling of osteoporosis have become as one of the important public hygiene problem of social concerns and the most popular research field of medical circle.Osteoporotic factor is caused to specifically include that inherited genetic factors；The shortage of calcium and vitamin D；Oestrogen deficiencies；Hypoandrogenism and senescent deterioration.It is currently used for preventing and treat osteoporotic drug main to have the 3 big classes such as calcium preparation, vitamin D and bone resorption depressant, whole world extensive use after being ratified by FDA.For the more serious case of ratio, adopt this 3 kinds of medicine use in conjunction, calcium preparation provides osteoplastic raw material, vitamin D promotes the absorption of intestinal calcium and suppresses the loss of bone calcium, bone resorption depressant can suppress the too fast bone resorption speed of post menopausal and senile osteoporosis, triple combination applies, and has mutually coordinated effect.
Flos lupuli (Flos Humuli Lupuli) total flavones is through ethanol extraction from moraceae plants Flos lupuli (Flos Humuli Lupuli) H.lupulusLinn., the flavones ingredient that purification by macroporous resin obtains.It is mainly chalcone, flavonoid and flavanoid containing flavones ingredient, including xanthohumol, isoxanthohumol, demethyl xanthohumol, Dehydrocycloxanthohumol hydrate, D, G, H, it it is the exclusive source of the natural prenylflavonoids having now been found that, it has also become the main source of xanthohumol and other prenylflavonoids.Wherein prenylflavonoids is current maximally effective phytoestrogen (Zhou Tian, brewing science and technology, the 8th phase in 2006)；From at present research it can be seen that Flos lupuli (Flos Humuli Lupuli) flavone has antiviral and antiplasmodial activities, antifungal, anticancer, estrogen-like effects, diglyceride Acetylase inhibitory action, antioxidation and bone resorption inhibitory action (Li Juan, Chinese herbal medicine, the 7th phase in 2008).
Os Cervi glycopeptide is the skeleton water high pressure extract of animal in deer family Cervus nippon Temminck CervusnipponTemminck or Cervus elaphus linnaeus CervuselaphusLinnaeus, after oil removing fat, precipitate with ethanol, and the glycopeptide compound obtained.Os Cervi is a kind of Chinese medicine, has effect of qi-restoratives, strong muscle, bone strengthening, it is adaptable to the diseases such as eipathia asthenia, marrow deficiency, anemia, rheumatism, extremity pain.Os Cervi glycopeptide has protection gastric mucosa, antiulcer, blood pressure lowering, pre-anti-osteoporosis, promote skin collagen metabolism, antioxidation, health care to wait for a long time physiological function.
The skeleton that Os Cervi activated calcium is animal in deer family Cervus nippon Temminck CervusnipponTemminck or Cervus elaphus linnaeus CervuselaphusLinnaeus adopts after Os Cervi glycopeptide homogenization process to smash through extracting, dry forms.
The dry mature fruit that Fructus Ligustri Lucidi extract is Oleaceae plants Fructus Ligustri Lucidi (LigustrumlucidumAit) utilizes ethanol extraction to obtain.Its nature and flavor sweetness and bitterness, cool, enter liver, kidney channel, there is effect of nourishing the liver and kidney, improving eyesight black hair, be used for treating the diseases such as vertigo and tinnitus, soreness of the waist and knees, early whitening of beard and hair, poor vision.Fructus Ligustri Lucidi mainly contains the triterpenes fat-soluble active ingredients such as oleanolic acid, water-soluble chemical component (the Wu Lijun such as secoiridoid glycoside and salidroside class, Botany Gazette, 1998,1st phase), vitamin D sample active substance and estrogen-like product, possibly together with a small amount of polysaccharide, phospholipid and inorganic elements.Modern pharmacological research shows, Fructus Ligustri Lucidi has nourishing the liver and kidney, antiinflammatory, raising immunity of organism, blood fat reducing and anti-aging effects (Jin Xiaoming, Chinese medicine information, the 2008, the 1st phase).
The present invention is made up of Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium and Fructus Ligustri Lucidi extract.Belonging to osteoporosis and suffering from a deficiency of the kidney, when making basic point with the kidney invigorating for the rule for the treatment of, in conjunction with the Couple herbs to osteoporosis in the modern age, through the side's of tearing open experiment, several times screening adjustment forms.Before the present patent application, do not find that the compositions of Fructus Ligustri Lucidi extract composition has the report of anti-curing osteoporosis by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium.
Summary of the invention
Compositions of the present invention is formed by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium and Fructus Ligustri Lucidi extract prescription, with traditional Chinese medical science the kidney invigorating, bone and muscle strengthening, replenishing QI to invigorate the spleen, tune liver of invigorating blood circulation are basic point, set out in conjunction with different mechanism of action such as supplement calcium, vitamin D and activated product, replenishing collagen, sex hormone level regulation, comprehensive function, in body, embodies the advantage of drug combination, reaches prevention preferably and the effect for the treatment of osteoporosis.
In the present composition, Flos lupuli (Flos Humuli Lupuli) total flavones has sex hormone level adjustment, corrects bone metabolism disturbance and suppresses bone resorption, promoting calcareous utilization；Os Cervi glycopeptide nourishing YIN and benefiting blood, logical conception vessel and nourishing YIN for suppressing the hyperactive YANG, kidney tonifying promotes the production of body fluid, it is provided that substantial amounts of ossein, promotes the absorption of calcium；Os Cervi activated calcium provides calcium former, nourishing YIN for suppressing the hyperactive YANG same with Os Cervi glycopeptide, kidney tonifying bone strengthening；Fructus Ligustri Lucidi extract nourishing the liver and kidney, provides vitamin D sample active substance and estrogen-like product to promote the absorption of calcium simultaneously.The extract mechanism of action four kinds different is different, and mutually works in coordination with again, enhances curative effect, has obvious novelty and technological progress.One important feature of medicine of the present invention is containing abundant nutrition ionized calcium, animal glycopeptide and total flavones, triterpene acids, vitamin D sample active substance, estrogen, various trace elements etc. in medicament.Whole drug component negative and positive are trained mutually, and cold not dry, application crowd is extensive, are rather in step with for all diseases caused by deficiency of kidney-essence.Four kinds of extract couplings of we can Ca,P metabolism in regulating muscle body, increase especially as the age, hormone in vivo level declines and causes the loss of body calcium, can the kidney invigorating, reuniting the fractured tendons and bones, blood circulation regulating, improve the symptom of aching pain in waist and back, the foot and knee being feeble.Senile osteoporosis can be made especially fundamentally to obtain the effective treatment.The invention has the beneficial effects as follows: to improving middle-aged and elderly people, particularly in women post menopausal body, calcium, phosphorus balance have facilitation, energy the kidney invigorating, reuniting the fractured tendons and bones, blood circulation regulating, can improve the symptom of aching pain in waist and back, the foot and knee being feeble.Bone density, bone mineral content can be significantly improved, there is the osteoporotic curative effect of significant treatment.The present invention has evident in efficacy, and cost is low, formula is clearly simple, and one-tenth is distinguished one from the other, system easy to control the quality, and other organ-tissue toxic and side effects are little, can long-term taking, have keep fit, strong bone function, the disease such as osteoporosis, fracture is all had significant curative effect.
The innovative point of the present invention is in that: the present invention utilizes edible Flos lupuli (Flos Humuli Lupuli) for primary raw material first, be equipped with again can be used for health food Os Cervi glycopeptide, Os Cervi activated calcium, Fructus Ligustri Lucidi extract composition compositions for preventing and treating osteoporosis, there is obvious novelty.Take full advantage of Os Cervi resource simultaneously, develop being made that outstanding contributions for deer industry further.
Another innovative point of the present invention is: Os Cervi is passed through extraction, oil removing fat by the present invention first, respectively obtaining offer human body and easily absorb Os Cervi glycopeptide and free Os Cervi activated calcium, Os Cervi is relatively directly pulverized and is taken absorption of human body of being more convenient for by this Os Cervi glycopeptide prepared through high pressure extract and Os Cervi activated calcium.Meanwhile, Os Cervi is through high pressure extract, and concentration, after drying, the pathogen in Os Cervi obtains removing, takes safety, and this is another beneficial effect of the present invention.The content of the middle polysaccharide of the Os Cervi glycopeptide extracted is 30-70%, and the content of protein is 35-75%.
The present invention relates to Os Cervi glycopeptide and Os Cervi activated calcium, be not limited in Os Cervi glycopeptide and Os Cervi activated calcium, when this prescription forms, Os Bovis seu Bubali and Os Caprae seu Ovis also have similar pharmacologically active.Os Cervi is replaced with Os Bovis seu Bubali and Os Caprae seu Ovis has the effect identical with the present invention.
The prevention effect of osteoporosis is substantially better than positive control medicine LONGMU ZHUANGGU CHONGJI and fully stocked wood board Os Cervi calcium tablet by Chinese medicine composition of the present invention, has obvious technological progress.
The present invention has pure natural, determined curative effect relative to prior art, has no side effect, the advantage such as taking convenience.
The invention also discloses one have auxiliary prevention and treat osteoporotic natural drug composition, it is characterized in that, it is made up of Flos lupuli (Flos Humuli Lupuli) total flavones 50-150 part, Os Cervi glycopeptide 25-100 part, Os Cervi activated calcium 150-400 part, Fructus Ligustri Lucidi extract 150-400 part, it is preferable that Flos lupuli (Flos Humuli Lupuli) total flavones 100 parts, Os Cervi glycopeptide 50 parts, Os Cervi activated calcium 200 parts, Fructus Ligustri Lucidi extract 200 parts.
The preparation method of natural drug composition of the present invention is as follows:
(1) Flos lupuli (Flos Humuli Lupuli) 30-95% alcohol reflux 2-3 time, each 2-3 hour, filter, filtrate recycling ethanol, the concentrated solution AB-8 macroporous resin column by anticipating, first use deionized water eluting, use 60-90% ethanol elution again, collect ethanol elution, reclaim ethanol, dry, obtain Flos lupuli (Flos Humuli Lupuli) total flavones；
(2) Os Cervi clear water is cleaned, and is ground into coarse powder, carries out high pressure extract 3 hours with the deionized water of 5 times amount in autoclave, filter, filtering residue add again 4 times amount deionized waters continue extract to Os Cervi loosen frangible, filter, merge twice filtrate, let cool, oil removing, concentration, the concentrated solution ethanol of 5 times amount precipitates, filter, dry, obtain Os Cervi glycopeptide；
(3) the Os Cervi refiner after extraction glycopeptide is broken into homogenate, dry, pulverize, cross 200 mesh sieves, obtain Os Cervi activated calcium；
(4) Fructus Ligustri Lucidi 4-10 times of 40-90% alcohol reflux 2-3 time, each 1-3 hour, filters, filtrate recycling ethanol, concentration, dry, obtains Fructus Ligustri Lucidi extract；
(5) by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium, Fructus Ligustri Lucidi extract proportionally mix homogeneously, add auxiliary materials and mixing, to obtain final product.
In order to realize above technical scheme, it is verified by method once:
Determination of polysaccharide in Os Cervi glycopeptide
The preparation of DNS reagent: take 3,5-dinitrosalicylic acid 6.5g, be dissolved in a small amount of water, move in 1000mL volumetric flask, adds 2mol/LNaOH solution 325mL, then adds people's 45g glycerol, shake up, be settled to scale.
The extraction precision of Os Cervi glycopeptide total sugar weighs Os Cervi glycopeptide 200mg and puts in 100mL test tube, adds 16mol/LHCl20mL, distilled water 30mL, boiling water boiling 60min, filters, adds 1 phenolphthalein reagent, being neutralized to blush with 10%NaOH solution, constant volume is in 250ml volumetric flask, stand-by.
It is appropriate that the preparation precision of reference substance weighs dextrose standard sample, is dissolved in water, makes the reference substance solution of 0.5mg/mL.
Glucose control product 0,0.5,1.0,1.2,1.5,2.0mL are drawn in the preparation of standard curve respectively, put in 25mL volumetric flask, add water 2.0,1.5,1.0,0.8,0.5 respectively, 0mL, respectively add 3mLDNS reagent, shake up, in boiling water boiling 5min, cooling, be settled to scale with distilled water.It is measured at 503nm place, calculates regression equation.
Mensuration takes 1.0mL extracting solution from above-mentioned liquid to be measured and puts in 25ml volumetric flask, then adds 1.0mL water, and adds DNS3mL, and after boiling water boiling 5min, flowing water cooling, adds water and be settled to 25mL, be measured at 503nm place, calculates content.
Protein content determination in Os Cervi glycopeptide
The preparation of reagent: reagent first (A): 10g sodium carbonate, 2g sodium hydroxide and 0.25g sodium potassium tartrate tetrahydrate add distilled water and be made into 500mL solution, reagent first (B): 0.5g copper sulfate is dissolved in 100mL distilled water, 50 parts (A) and 1 part (B) are mixed into reagent first by each used time.Reagent second: 100g sodium tungstate, 25g sodium molybdate and 700mL distilled water, add 50mL85% phosphoric acid again, the dense HCl of 100mL is sufficiently mixed, and after backflow 10h, adds 150g lithium sulfate, 50mL distilled water and number drop of liquid bromine, opening continues boiling 15min to drive away excessive bromine, is diluted to 1L, filters after cooling, filtrate preserves in brown bottle, is reagent second again with front dilution 1.
The preparation precision of reference substance solution weighs 105 DEG C and is dried to constant weight bovine serum albumin reference substance, puts in measuring bottle, is dissolved in water and is diluted to scale, shaking up, and obtains (every 1mL is containing bovine serum albumin 300 μ g).
The preparation of standard curve take bovine serum albumin standard solution 0,0.4,0.8,1.6,2.0mL add in 5 test tubes, standard solution moisturizing, to 2mL, adds 5mL reagent first, shake up, static 10min, is subsequently adding 0.5mL reagent second, and vibration immediately shakes up, after static 30min, with standard solution the 1st pipe for comparison, according to spectrophotography (" Chinese Pharmacopoeia " 2010 editions annex VA), measure trap at 660nm wavelength place, with the trap that bovine serum albumin μ g number is corresponding, calculate regression equation.
Assay method precision weighs test sample, and to be configured to solution concentration be 600 μ g/mL, as need testing solution.The accurate need testing solution 1.0mL that draws adds water to 2mL, under sighting target directrix curve preparation from " adding 5mL reagent first ", operates in accordance with the law, measures trap, by regression equation calculation protein content.
Composition of natural products of the present invention has prevents and treats osteoporosis function, is confirmed (experiment Pharmaceutical composition used is the Pharmaceutical composition prepared in embodiment 1) by following pharmacodynamic experiment.
The test medicine present composition prepares according to example 1；Positive control drug LONGMU ZHUANGGU KELI is Wuhan JianMin Pharmaceutical Group Co., Ltd's product, lot number 1311001.Big deep woods board Os Cervi calcium tablet is Daqing Huake Company Limited. Pharmacy filiale's product, lot number: 130201.
Animal SD rat, female, at three monthly ages, body weight 213 ± 21g, purchased from Jilin University's Experimental Animal Center, the quality certification number 13008.The quality certification number deletes can also
Therapeutical effect on castrated rats osteoporosis disease: main investigate the present composition impact on rat femur bone density and rat femur bone index, the impact on rat blood serum calcium, serum paraoxonase, divides rat femur bone ash, the impact of bone calcium, bone phosphorus.
Take male and female rat (body weight 160g 180g) half and half, anaesthetize with 3% pentobarbital sodium, routine disinfection, aseptically extract bilateral testes or ovary, sew up the incision at random, sham operated rats is only done to sew up (not Testectomy and ovary) again after abdominal operation sterilization is cut, by rat random packet, often group 10, it is grouped after performing the operation one week, it is administered by medication group, once a day, continuous 90 days, compositions administration group presses 800mg/kg, 400mg/kg, 200mg/kg is high, in, low three administration groups administration, positive control LONGMU ZHUANGGU KELI 0.8mg/kg, the deep greatly woods board Os Cervi calcium tablet 800mg/kg of positive control, matched group and model group are given and coordinative solvent.Observation index: administration terminates broken end sudden death animal, take blood system from serum, measure S/Ca, S/P content by kit method, take rats with bilateral femur and peel meat and hetero-organization thereof off, wherein side femur does bone density scan on Dual-energy X-rays absorptionmetry, measures bone density (g/cm2), claiming femur weight (W), survey bone length (L), dry 1 hour for 110 DEG C, then put in Muffle furnace 200 DEG C, 400 DEG C, 600 DEG C, 800 DEG C each ashing two hours, ashing terminates, and cooling claims ash weight (Wash), with the HNO of 6N3Survey bone ash P, Ca content after extraction, represent with the grams of 100g bone ash calcium ions or P.Result above all compares with administration group and model group, and model group and matched group compare.Experimental result is in Table 1,2,3.
The impact on rat femur bone density and rat femur bone index of table 1, this compositions
△△P < 0.01 compares with Normal group,*P < 0.05,**P < 0.01 compares with model control group
The impact on rat blood serum calcium, serum paraoxonase of table 2, this compositions
△△P < 0.01 compares with Normal group,*P < 0.05,**P < 0.01 compares with model control group
Rat femur bone ash is divided by table 3, this compositions, the impact of bone calcium, bone phosphorus
△△P < 0.01 compares with Normal group,*P < 0.05,**P < 0.01 compares with model control group
Result above shows that castrated rats femoral bmd, bone weight, bone ash weight, bone calcium, bone phosphorus are all had appreciable impact by the present composition so that it is increase, and bone length is not affected, make serum calcium increase, and serum paraoxonase impact is less.
In the present invention, compositions has increase bone density in sum, prevents and treats osteoporotic effect.
The present invention is described in detail by the following examples, but is not intended that the invention is limited to this, and specific embodiments is as follows:
Embodiment 1Prepared by the extraction of compositions
(1) Flos lupuli (Flos Humuli Lupuli) 60% alcohol reflux 2 times, when each 2, filter, filtrate recycling ethanol, add water to every ml containing 0.6g crude drug, by the AB-8 macroporous resin column anticipated, first with 4 times of column volumes of deionized water eluting, then with 4 times of column volumes of 70% ethanol elution, collect ethanol elution, reclaim ethanol, dry, obtain Flos lupuli (Flos Humuli Lupuli) total flavones；
(2) Os Cervi clear water is cleaned, and is ground into coarse powder, carries out high pressure extract 3 hours with the deionized water of 5 times amount in autoclave, filter, filtering residue add again 4 times amount deionized waters continue extract to Os Cervi loosen frangible, filter, merge twice filtrate, let cool, oil removing, concentration, the concentrated solution ethanol of 5 times amount precipitates, filter, filter residue and drying, obtain Os Cervi glycopeptide；
(3) the Os Cervi refiner after extraction glycopeptide is broken into homogenate, dry, pulverize, cross 200 mesh sieves, obtain Os Cervi activated calcium；
(4) Fructus Ligustri Lucidi 6 times of 70% alcohol reflux 3 times, each 2 hours, filters, filtrate recycling ethanol, concentration, dry, obtains Fructus Ligustri Lucidi extract；
(5) by Flos lupuli (Flos Humuli Lupuli) total flavones 100 parts, Os Cervi glycopeptide 50 parts, Os Cervi activated calcium 200 parts, Fructus Ligustri Lucidi extract 200 parts, after mix homogeneously, add adjuvant uniformly, to obtain final product.
Claims (3)
1. an auxiliary is prevented and treats osteoporotic natural drug composition, it is characterized in that, it is made up of the raw material of following weight parts: Flos lupuli (Flos Humuli Lupuli) total flavones 50-150 part, Os Cervi glycopeptide 25-100 part, Os Cervi activated calcium 150-400 part, Fructus Ligustri Lucidi extract 150-400 part；The preparation method of described compositions is as follows:
(1) Flos lupuli (Flos Humuli Lupuli) 30-95% alcohol reflux 2-3 time, each 2-3 hour, filter, filtrate recycling ethanol, the concentrated solution AB-8 macroporous resin column by anticipating, first use deionized water eluting, use 60-90% ethanol elution again, collect ethanol elution, reclaim ethanol, dry, obtain Flos lupuli (Flos Humuli Lupuli) total flavones；
(2) Os Cervi clear water is cleaned, and is ground into coarse powder, carries out high pressure extract 3 hours with the deionized water of 5 times amount in autoclave, filter, filtering residue add again 4 times amount deionized waters continue high pressure extract to Os Cervi loosen frangible, filter, merge twice filtrate, let cool, oil removing, concentration, the concentrated solution ethanol of 5 times amount precipitates, filter, dry, obtain Os Cervi glycopeptide；
(3) the Os Cervi refiner after extraction glycopeptide is broken into homogenate, dry, pulverize, cross 200 mesh sieves, obtain Os Cervi activated calcium；
(4) Fructus Ligustri Lucidi 4-10 times of 40-90% alcohol reflux 2-3 time, each 1-3 hour, filters, filtrate recycling ethanol, concentration, dry, obtains Fructus Ligustri Lucidi extract；
(5) by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium, Fructus Ligustri Lucidi extract proportionally mix homogeneously, add auxiliary materials and mixing, to obtain final product.
2. a kind of auxiliary is prevented and treats osteoporotic natural drug composition according to claim 1, it is characterized in that, it is made up of the raw material of following weight parts: Flos lupuli (Flos Humuli Lupuli) total flavones 100 parts, Os Cervi glycopeptide 50 parts, Os Cervi activated calcium 200 parts, Fructus Ligustri Lucidi extract 200 parts；The preparation method of described compositions is as follows:
(1) Flos lupuli (Flos Humuli Lupuli) 30-95% alcohol reflux 2-3 time, each 2-3 hour, filter, filtrate recycling ethanol, the concentrated solution AB-8 macroporous resin column by anticipating, first use deionized water eluting, use 60-90% ethanol elution again, collect ethanol elution, reclaim ethanol, dry, obtain Flos lupuli (Flos Humuli Lupuli) total flavones；
(2) Os Cervi clear water is cleaned, and is ground into coarse powder, carries out high pressure extract 3 hours with the deionized water of 5 times amount in autoclave, filter, filtering residue add again 4 times amount deionized waters continue high pressure extract to Os Cervi loosen frangible, filter, merge twice filtrate, let cool, oil removing, concentration, the concentrated solution ethanol of 5 times amount precipitates, filter, dry, obtain Os Cervi glycopeptide；
(3) the Os Cervi refiner after extraction glycopeptide is broken into homogenate, dry, pulverize, cross 200 mesh sieves, obtain Os Cervi activated calcium；
(4) Fructus Ligustri Lucidi 4-10 times of 40-90% alcohol reflux 2-3 time, each 1-3 hour, filters, filtrate recycling ethanol, concentration, dry, obtains Fructus Ligustri Lucidi extract；
(5) by Flos lupuli (Flos Humuli Lupuli) total flavones, Os Cervi glycopeptide, Os Cervi activated calcium, Fructus Ligustri Lucidi extract proportionally mix homogeneously, add auxiliary materials and mixing, to obtain final product.
3. an auxiliary is prevented and treats osteoporotic natural drug composition oral formulations, it is characterized in that mixing the natural drug composition one of claim 1-2 Suo Shu with pharmaceutic adjuvant, making oral formulations, it is any one in hard capsule, soft capsule, tablet, granule, powder, pill, teabag, medicated wine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410551423.2A CN104257762B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410551423.2A CN104257762B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104257762A CN104257762A (en) | 2015-01-07 |
| CN104257762B true CN104257762B (en) | 2016-07-06 |
Family
ID=52149419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410551423.2A Expired - Fee Related CN104257762B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104257762B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105232634A (en) * | 2015-10-12 | 2016-01-13 | 临沂草之美医药科技有限公司 | Application of pharmaceutical composition for preparing osteoporosis treating drug |
| CN106880839B (en) * | 2015-12-14 | 2021-07-13 | 吉林省东鳌鹿业集团有限公司 | Deer bone tablet and preparation method thereof |
| CN105663239B (en) * | 2016-03-08 | 2020-11-10 | 宁夏医科大学 | Application of lindera communis leaf extract in preparation of medicine for treating osteoporosis and medicine composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239083A (en) * | 2007-02-09 | 2008-08-13 | 普尔药物科技开发（深圳）有限公司 | New medical purpose of privet and pharmaceutical formulation thereof |
| CN101711161A (en) * | 2007-03-19 | 2010-05-19 | 麦特普罗泰欧米克斯有限公司 | Promote the method and composition of skeleton and articulation health |
-
2014
- 2014-10-17 CN CN201410551423.2A patent/CN104257762B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239083A (en) * | 2007-02-09 | 2008-08-13 | 普尔药物科技开发（深圳）有限公司 | New medical purpose of privet and pharmaceutical formulation thereof |
| CN101711161A (en) * | 2007-03-19 | 2010-05-19 | 麦特普罗泰欧米克斯有限公司 | Promote the method and composition of skeleton and articulation health |
Non-Patent Citations (1)
| Title |
|---|
| 女贞子的药理作用及其临床应用进展;金芝贵等;《药学服务与研究》;20110630;第11卷(第03期);189-192 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104257762A (en) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105412569A (en) | Composition for increasing bone mineral density and preparation and preparation method thereof | |
| CN101428056A (en) | Health care formulation for improving osteoporosis of female in middle and old age and preparation method thereof | |
| CN106110291A (en) | A kind of nutritional preparation for kidney cell reparation and preparation method thereof | |
| CN104257762B (en) | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of | |
| CN102846906A (en) | Medicament for treating premature ovarian failure and preparation method thereof | |
| CN101612279B (en) | Chinese medicine preparation for promoting fracture healing | |
| CN104127861B (en) | A kind of have pharmaceutical composition increasing bone density effect and preparation method thereof | |
| CN106963811A (en) | A kind of draft liquid with promoting blood circulation, removing blood stasis and relieving pain | |
| CN103349674B (en) | Tortoise shell rana japonica oil composition for increasing bone density and preventing osteoporosis | |
| CN103405755B (en) | Pharmaceutical composition for treating primary osteoporosis | |
| CN104001157B (en) | Compound preparation of a kind of protect against osteoporosis and preparation method thereof | |
| CN106361947A (en) | Preparation method of traditional Chinese medicine for treating osteoporosis | |
| CN106620402A (en) | Traditional Chinese medicine composition taken after operation of liver cancer and preparation method thereof | |
| CN106362067A (en) | Roxburg rose fruit appetite improving and digestion promoting drug composition and preparation method thereof | |
| CN102114070A (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN104189693B (en) | Traditional Chinese medicine composition for treating posemenopausal osteoporosis | |
| CN1330325C (en) | Medicine for preventing and curing osteoporosis and its preparing method | |
| CN103705856B (en) | For preventing the Chinese medicine composition of chemicotherapy acute radio-reaction | |
| CN103690644B (en) | Promote the Chinese medicine preparation of fracture recovering | |
| CN102961518B (en) | Application for ginseng-rhizoma curculiginis combined medicine for preparation for medicine used for treating osteoporosis | |
| CN107115424A (en) | Change acidic constitution and protect calcium and clearing heat and detoxicating Chinese medicine composition and preparation method | |
| CN107913389A (en) | A kind of Chinese medicine composition for treating Thyroid Gland Swell and preparation method thereof | |
| CN100571739C (en) | Herbal mixture of treatment cardiovascular disease and preparation method thereof | |
| CN102552386B (en) | Anti-osteoporosis Chinese medicinal preparation and preparation method thereof | |
| CN104771454B (en) | A kind of pharmaceutical composition for the treatment of of acute radiation oral mucositis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yin Yuhe Inventor after: Teng Guosheng Inventor after: Wu Congmei Inventor after: He Yufang Inventor after: Nan Minlun Inventor after: Zhao Quancheng Inventor before: Zhao Quancheng Inventor before: Nan Minlun Inventor before: Zhao Yuwei Inventor before: He Yufang Inventor before: Ma Jisheng Inventor before: Lv Na Inventor before: He Zhongmei |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160530 Address after: 130021 College of chemistry and life science, Yanan Road, Changchun, Jilin, China Applicant after: Changchun Polytechnic Univ. Address before: High tech Zone of Jilin province Changchun pioneering street 130012 No. 155 Jilin Provincial Academy of traditional Chinese Medicine Applicant before: Zhao Quancheng |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160706 Termination date: 20201017 |